Yarrow Bioscience (NASDAQ:YARW) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Yarrow Bioscience (NASDAQ:YARW – Get Free Report) have been assigned an average rating of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $52.67.

A number of equities analysts have issued reports on the company. BTIG Research initiated coverage on Yarrow Bioscience in a research note on Monday, August 3rd. They set a “buy” rating and a $58.00 price target for the company. Jefferies Financial Group set a $40.00 price objective on Yarrow Bioscience and gave the stock a “buy” rating in a research note on Monday. Wall Street Zen raised Yarrow Bioscience to a “hold” rating in a research note on Saturday, August 22nd. Guggenheim started coverage on Yarrow Bioscience in a report on Friday, November 6th. They issued a “buy” rating and a $60.00 price objective for the company. Finally, TD Cowen assumed coverage on Yarrow Bioscience in a research note on Tuesday, July 28th. They set a “buy” rating for the company.

Get Our Latest Stock Analysis on Yarrow Bioscience

Institutional Investors Weigh In On Yarrow Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC bought a new position in shares of Yarrow Bioscience during the 2nd quarter valued at about $26,000. BlackRock Inc. acquired a new position in shares of Yarrow Bioscience in the 2nd quarter worth approximately $29,000. GSA Capital Partners LLP bought a new stake in shares of Yarrow Bioscience in the 2nd quarter worth approximately $47,000. Rangeley Capital LLC raised its holdings in shares of Yarrow Bioscience by 18.1% in the 1st quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock worth $71,000 after purchasing an additional 18,064 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new stake in shares of Yarrow Bioscience in the 2nd quarter worth approximately $77,000. 83.78% of the stock is currently owned by institutional investors.

Yarrow Bioscience Price Performance

Yarrow Bioscience stock opened at $18.03 on Monday. Yarrow Bioscience has a 12-month low of $12.39 and a 12-month high of $46.95. The company has a market capitalization of $48.14 million, a PE ratio of -1.23 and a beta of 2.10. The company has a 50 day moving average of $21.88.

Yarrow Bioscience (NASDAQ:YARW – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.43) EPS for the quarter. Yarrow Bioscience had a negative return on equity of 99.84% and a negative net margin of 4,726.21%.

Yarrow Bioscience Company Profile

(Get Free Report)

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.

Featured Stories

Analyst Recommendations for Yarrow Bioscience (NASDAQ:YARW)

Receive News & Ratings for Yarrow Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yarrow Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.